Terbinafine
Side effects
Options:
Show MedDRA Preferred Terms,
display all 22 labels
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
19
|
20
|
Abdominal cramps
|
very common
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
|
x
|
Anorexia
|
very common
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
x
|
|
|
x
|
|
x
|
Eructation
|
very common
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
|
x
|
Gastritis
|
very common, 2.2% - 22%
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
x
|
|
|
x
|
|
x
|
Abdominal discomfort
|
very common
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
|
x
|
Appetite absent
|
very common
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
x
|
|
|
x
|
|
|
Nasopharyngitis
|
10% - 11%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Headache
|
common, 0.2% - 12.9%
|
0% - 9.5%
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Cough
|
5% - 6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Cramp muscle
|
1% - 10%
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Erythema
|
common, 0.9% - 9%
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
x
|
|
|
x
|
|
x
|
Upper respiratory tract infection
|
5%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Abdominal pain upper
|
4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Diarrhoea
|
very common, 0% - 10%
|
0% - 2.9%
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Dyspepsia
|
very common, 0% - 22%
|
0% - 2.9%
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Dizziness
|
very rare, common
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
|
x
|
|
x
|
Nausea
|
very common, 0% - 11%
|
0% - 2.9%
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Flatulence
|
very common, 0% - 2.2%
|
0% - 2.2%
|
|
|
x
|
x
|
x
|
x
|
|
|
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
|
x
|
Rash
|
common, 0.7% - 9%
|
0.7% - 2.2%
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Pharyngolaryngeal pain
|
2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Skin disorder
|
1.9%
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Abdominal pain
|
0% - 2.4%
|
0% - 1.5%
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
|
x
|
|
Influenza
|
1% - 2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Nasal congestion
|
1% - 2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Pruritus
|
common, 0% - 4%
|
0% - 1.5%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Toothache
|
1%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Skin exfoliation
|
1%
|
|
x
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rhinorrhoea
|
0% - 2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Visual disturbance
|
0% - 1.5%
|
0% - 1.5%
|
|
|
x
|
x
|
x
|
x
|
|
|
|
x
|
x
|
x
|
|
|
|
x
|
x
|
|
|
|
Rash erythematous
|
0.9%
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Urticaria
|
common, 0% - 5%
|
0%
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Vomiting
|
postmarketing — 1.1% - 11%
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Eczema
|
0.1% - 1%
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Hypoglycaemia
|
0.1% - 1%
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Pain
|
0.1% - 1%
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Dry mouth
|
0.1% - 1%
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Sickness
|
0.1% - 1%
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Hepatic enzyme increased
|
0.1% - 1%
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Agranulocytosis
|
very rare, postmarketing
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Alopecia
|
postmarketing
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Anaphylactic shock
|
postmarketing
|
|
|
|
x
|
x
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Anaemia
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Angioedema
|
very rare, postmarketing
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Anosmia
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Anxiety
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Arthralgia
|
postmarketing, very common
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Mental disorder
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
x
|
x
|
Cholestasis
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
x
|
|
Connective tissue disorder
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Dermatitis exfoliative
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
x
|
x
|
Dysgeusia
|
postmarketing — 0% - 2.8%
|
0% - 0.7%
|
|
|
x
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
|
|
|
x
|
x
|
|
x
|
x
|
Eosinophilia
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
x
|
x
|
Toxic epidermal necrolysis
|
postmarketing
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Erythema multiforme
|
postmarketing
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Eye disorder
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
x
|
x
|
Fatigue
|
very rare — 0.3% - 3%
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Body temperature increased
|
postmarketing, 6% - 7%
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Gastrointestinal disorder
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
x
|
x
|
x
|
x
|
Hepatitis
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
x
|
|
Hypersensitivity
|
postmarketing
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
x
|
x
|
|
Hypoaesthesia
|
very rare — uncommon
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Immune system disorder
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
x
|
Jaundice cholestatic
|
rare
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
|
x
|
Systemic lupus erythematosus
|
very rare, postmarketing
|
|
|
|
x
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Nervous system disorder
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Neutropenia
|
very rare, postmarketing
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Pancreatitis
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Pancytopenia
|
very rare, postmarketing
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Paraesthesia
|
very rare — uncommon
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Rhabdomyolysis
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Scotoma
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
|
x
|
x
|
|
x
|
|
Stevens-Johnson syndrome
|
postmarketing
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Thrombocytopenia
|
very rare, postmarketing
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Tinnitus
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Angiopathy
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Vasculitis
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
x
|
|
x
|
x
|
x
|
x
|
Vertigo
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
|
|
|
x
|
x
|
|
x
|
|
Weight decreased
|
postmarketing
|
|
|
|
x
|
x
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Hepatic failure
|
very rare — rare
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Dermatitis bullous
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
x
|
x
|
Depressive symptom
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Liver injury
|
postmarketing
|
|
|
|
x
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
|
|
|
x
|
x
|
|
x
|
|
Photosensitivity reaction
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
|
x
|
x
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Unspecified disorder of skin and subcutaneous tissue
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Serum sickness-like reaction
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Malaise
|
postmarketing
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
|
x
|
|
Myalgia
|
postmarketing, very common
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Visual acuity reduced
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
|
x
|
x
|
|
x
|
x
|
Psoriasis flare-up
|
very rare, postmarketing
|
|
|
|
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Dermatitis psoriasiform
|
postmarketing
|
|
|
|
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
|
x
|
|
Hepatobiliary disease
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
x
|
Influenza like illness
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Blood and lymphatic system disorders
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Ear and labyrinth disorders
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
x
|
x
|
Blood creatine phosphokinase increased
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Vasculitis gastrointestinal
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Acute generalised exanthematous pustulosis
|
postmarketing
|
|
|
|
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Hearing impaired
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Ageusia
|
postmarketing — common
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Chest pain
|
very rare
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
|
x
|
Blood disorder
|
very rare
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
x
|
|
|
x
|
|
x
|
Lightheadedness
|
very rare
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
|
x
|
Eruption
|
very rare
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
|
x
|
Anaphylactoid reaction
|
very rare
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
x
|
|
|
x
|
|
x
|
Arthritis
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Infection
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Confusional state
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Drug eruption
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Dermatitis contact
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ear disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
x
|
Partial hearing loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
x
|
Jaundice
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Liver disorder
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Polymorphic light eruption
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Thrombotic thrombocytopenic purpura
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Serum sickness
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Hepatic function abnormal
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Skin discolouration
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hypogeusia
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Skin hyperpigmentation
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fatal outcomes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Decreased appetite
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Bullous eruption
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
|
Photosensitivity allergic reaction
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Redness
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
|
Vision blurred
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Photosensitivity
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Lupus erythematosus
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
|
|
Gastrointestinal symptom NOS
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
|
|
|
x
|
x
|
|
|
|
Rash generalised
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
|
Toxic skin eruption
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Stinging
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
|
Haematocrit decreased
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Infestation NOS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Serum urea increased
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
x
|
Photodermatosis
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Hyposmia
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
|
x
|
Visual impairment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Side effects: | 4 |
Source: | FDA |
---|
Side effects: | 6 |
Source: | FDA |
---|
Side effects: | 29 |
Source: | FDA |
---|
Side effects: | 32 |
Source: | FDA Structured Product Label |
---|
Side effects: | 32 |
Source: | FDA Structured Product Label |
---|
Side effects: | 32 |
Source: | FDA Structured Product Label |
---|
Side effects: | 45 |
Source: | Health Canada |
---|
Side effects: | 46 |
Source: | Health Canada |
---|
Side effects: | 47 |
Source: | FDA Structured Product Label |
---|
Side effects: | 47 |
Source: | FDA Structured Product Label |
---|
Side effects: | 48 |
Source: | FDA Structured Product Label |
---|
Side effects: | 51 |
Source: | FDA Structured Product Label |
---|
Side effects: | 57 |
Source: | Health Canada |
---|
Side effects: | 61 |
Source: | Health Canada |
---|
Side effects: | 63 |
Source: | medicines.org.au |
---|
Side effects: | 70 |
Source: | FDA Structured Product Label |
---|
Side effects: | 71 |
Source: | FDA Structured Product Label |
---|
Side effects: | 72 |
Source: | medicines.org.au |
---|
Side effects: | 80 |
Source: | FDA Structured Product Label |
---|
Side effects: | 83 |
Source: | medicines.org.au |
---|
Color scheme:
standard – alternative
|
|
100%
|
|
|
75%
|
|
|
50%
|
|
|
10%
|
|
|
frequent (1% to 100%)
|
|
|
infrequent (0.1% to 1%)
|
|
|
rare (<0.1%)
|
|
|
postmarketing
|
|
|
0%
|
|
|
no frequency information
|
|
|
not found on label
|